Davis JE - Search Results

1

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.

Davis JE, Handunnetti SM, Ludford-Menting M, Sharpe C, Blombery P, Anderson MA, Roberts AW, Seymour JF, Tam CS, Ritchie DS, Koldej RM. Davis JE, et al. Blood Adv. 2020 Oct 13;4(19):4849-4859. doi: 10.1182/bloodadvances.2020002810. Blood Adv. 2020. PMID: 33031542 Free PMC article.

2

The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells.

Herst PM, Davis JE, Neeson P, Berridge MV, Ritchie DS. Herst PM, et al. Among authors: davis je. Haematologica. 2009 Jul;94(7):928-34. doi: 10.3324/haematol.2008.003996. Epub 2009 Jun 16. Haematologica. 2009. PMID: 19535345 Free PMC article.

3

B cells in GVHD: friend or foe?

Davis JE, Ritchie DS. Davis JE, et al. Blood. 2010 Mar 25;115(12):2558-9; author reply 2559-60. doi: 10.1182/blood-2009-11-254177. Blood. 2010. PMID: 20339111 Free article. No abstract available.

4

The passive-aggressive relationship between CLL-B cells and T cell immunity.

Davis JE, Ritchie DS. Davis JE, et al. Leuk Res. 2014 Oct;38(10):1160-1. doi: 10.1016/j.leukres.2014.08.005. Epub 2014 Aug 19. Leuk Res. 2014. PMID: 25182688 No abstract available.

5

A radio-resistant perforin-expressing lymphoid population controls allogeneic T cell engraftment, activation, and onset of graft-versus-host disease in mice.

Davis JE, Harvey M, Gherardin NA, Koldej R, Huntington N, Neeson P, Trapani JA, Ritchie DS. Davis JE, et al. Biol Blood Marrow Transplant. 2015 Feb;21(2):242-9. doi: 10.1016/j.bbmt.2014.11.003. Epub 2014 Nov 12. Biol Blood Marrow Transplant. 2015. PMID: 25459639 Free article.

6

Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib.

Neeson PJ, Hsu AK, Chen YR, Halse HM, Loh J, Cordy R, Fielding K, Davis J, Noske J, Davenport AJ, Lindqvist-Gigg CA, Humphreys R, Tai T, Prince HM, Trapani JA, Smyth MJ, Ritchie DS. Neeson PJ, et al. Oncoimmunology. 2015 May 27;4(9):e1038011. doi: 10.1080/2162402X.2015.1038011. eCollection 2015 Sep. Oncoimmunology. 2015. PMID: 26405606 Free PMC article.

7

CIK immunotherapy in refractory hematologic malignancies.

Wong E, Ritchie DS, Davis JE. Wong E, et al. Among authors: davis je. Leuk Res. 2016 Oct;49:60-1. doi: 10.1016/j.leukres.2016.08.005. Epub 2016 Aug 20. Leuk Res. 2016. PMID: 27561991 No abstract available.

8

Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation.

Wong E, Davis JE, Grigg A, Szer J, Ritchie D. Wong E, et al. Among authors: davis je. Bone Marrow Transplant. 2019 Feb;54(2):175-189. doi: 10.1038/s41409-018-0244-z. Epub 2018 Jun 14. Bone Marrow Transplant. 2019. PMID: 29904127 Review.

9

Comparison of gene expression and flow cytometry for immune profiling in chronic lymphocytic leukaemia.

Sharpe C, Davis J, Mason K, Tam C, Ritchie D, Koldej R. Sharpe C, et al. J Immunol Methods. 2018 Dec;463:97-104. doi: 10.1016/j.jim.2018.09.013. Epub 2018 Sep 26. J Immunol Methods. 2018. PMID: 30267664

10

Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes.

Jiao Y, Davis JE, Rautela J, Carrington EM, Ludford-Menting MJ, Goh W, Delconte RB, Souza-Fonseca-Guimaraes F, Koldej R, Gray D, Huang D, Kile BT, Lew AM, Ritchie DS, Huntington ND. Jiao Y, et al. Among authors: davis je. Cell Death Differ. 2019 Aug;26(8):1516-1530. doi: 10.1038/s41418-018-0228-y. Epub 2018 Nov 12. Cell Death Differ. 2019. PMID: 30420758 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

548 results

Search Page